Lumanity Executive and Leadership Team

Andrew Dreyfus, the President & Chief Executive Officer at Lumanity, directs the overarching strategy and operational execution for the organization. This leadership role involves guiding Lumanity's mission to accelerate and optimize access to medical advances through incisive thinking and decisive action. Overseeing global operations, the President & Chief Executive Officer ensures the company's transformative outcomes are delivered across North America, the United Kingdom, Europe, and Asia. By translating complex data into real-world insights, Andrew Dreyfus empowers patients, providers, payers, and regulators to make timely decisions. This executive drives the company's engagement with top pharmaceutical and biotech firms, focusing on demonstrating product value and securing sustainable market success. The strategic vision set by Andrew Dreyfus underpins Lumanity's ability to turn aspiration into reality, supporting successful development strategies, commercial launches, and product campaigns worldwide.

Rebecca Hyde, the Chief Operating Officer and Global Practice Lead, Value Access and Outcomes at Lumanity, manages the day-to-day operations and leads the global practice focused on value, access, and outcomes. This critical role ensures Lumanity's 1,200+ experts effectively generate evidence demonstrating product value and optimize commercialization strategies. Overseeing operational efficiency across Lumanity's global offices in North America, the UK, Europe, and Asia, Rebecca Hyde drives the transformation of data into actionable insights. The Global Practice Lead, Value Access and Outcomes ensures that Lumanity's work with pharmaceutical and biotech companies directly supports bringing medical advances to patients at a price reflective of their value. This leadership function involves translating complex science and data into compelling narratives relevant to global stakeholders, enabling commercial decisions for sustainable market success. Rebecca Hyde's operational oversight is fundamental to delivering successful development strategies and payer submissions.

Christopher Evans, the President Patient-Centered Outcomes at Lumanity, spearheads initiatives focused on understanding and demonstrating the value of medical advances from the patient's perspective. This leadership position involves directing the generation of evidence that empowers patients, providers, and payers to take decisive action regarding treatment access and utilization. Overseeing the patient-centered outcomes practice, Christopher Evans ensures Lumanity's deep experience in medical affairs translates into real-world insights that resonate with all stakeholders. The President Patient-Centered Outcomes drives the development of strategies that highlight the patient impact of pharmaceutical and biotech products, supporting commercialization efforts. By focusing on patient-centric evidence, Christopher Evans contributes significantly to Lumanity's mission of accelerating access to medical innovations. This role is crucial for translating scientific data into compelling narratives that underscore the real-world value and benefits for patients globally.

Robert Budreau, the President & Producer at Lumanity, drives strategic initiatives and oversees the production of key client deliverables that transform complex situations into tangible outcomes. This executive role focuses on ensuring Lumanity's incisive thinking is translated into decisive action, particularly in bringing medical advances to market. As President & Producer, Robert Budreau manages the execution of projects that demonstrate the value of pharmaceutical and biotech products, working closely with internal teams and external partners. This leadership function involves leveraging Lumanity's deep experience in commercial and regulatory affairs to power successful commercialization. By overseeing the production of evidence and insights, Robert Budreau directly supports Lumanity's mission to empower patients, providers, and payers. The strategic direction provided by Robert Budreau is essential for achieving successful development strategies and product launches.

Stephen Weisman, the Global President at Lumanity, directs the company's worldwide operations and strategic growth initiatives, ensuring consistent delivery of transformative outcomes. This executive leadership role encompasses overseeing Lumanity's extensive network of 1,200+ experts across North America, the United Kingdom, Europe, and Asia. As Global President, Stephen Weisman champions the company's mission to accelerate and optimize access to medical advances by applying incisive thinking and decisive action. This position involves fostering collaboration among teams working with top pharmaceutical and biotech companies to demonstrate product value and drive market success. Stephen Weisman's leadership ensures that Lumanity's deep experience in medical, commercial, and regulatory affairs is leveraged globally to transform data into real-world insights. The strategic oversight provided by Stephen Weisman is critical for enabling commercial decisions and supporting successful product campaigns worldwide.

Angela Wheeler, the President, Insights (US) at Lumanity, leads the strategic development and execution of insight generation within the United States market. This role is pivotal in transforming complex data and information into real-world evidence that powers successful commercialization of medical advances. Overseeing the insights function, Angela Wheeler ensures Lumanity's deep experience in commercial affairs is applied to identify and generate the evidence needed to demonstrate product value. The President, Insights (US) drives the translation of science and data into compelling product narratives relevant to US stakeholders, including patients, providers, and payers. By focusing on actionable insights, Angela Wheeler empowers timely and decisive action, supporting sustainable market success for pharmaceutical and biotech products. This leadership position is instrumental in shaping Lumanity's approach to market understanding and evidence generation within the critical US region.

Juliet Munakata, the Global President, HEOR at Lumanity, directs the Health Economics and Outcomes Research strategy worldwide, ensuring robust evidence generation to demonstrate product value. This executive role is central to Lumanity's mission of accelerating access to medical advances by providing critical data that supports payer submissions and commercialization efforts. Overseeing global HEOR initiatives, Juliet Munakata leverages deep expertise in medical and regulatory affairs to translate scientific findings into compelling value propositions. The Global President, HEOR works closely with pharmaceutical and biotech clients to identify and generate the evidence required to position products effectively in the market. By ensuring the rigorous application of HEOR principles, Juliet Munakata empowers stakeholders to take decisive action based on real-world insights. This leadership function is essential for achieving sustainable success and demonstrating the true value of medical innovations globally.

Marissa Poli, the President at Lumanity, drives strategic initiatives and operational excellence across key business functions, contributing to the company's transformative outcomes. This leadership role focuses on translating Lumanity's incisive thinking into decisive action, ensuring the acceleration and optimization of access to medical advances. Overseeing specific operational areas, Marissa Poli ensures that data and information are transformed into real-world insights that empower patients, providers, and payers. The President works to demonstrate the value of pharmaceutical and biotech products, supporting their successful commercialization. By enabling commercial decisions that position products for sustainable success, Marissa Poli plays a vital part in Lumanity's mission. This executive's focus on execution is critical for delivering successful development strategies and product campaigns, turning aspiration into reality for clients worldwide.

John Howley, the President, Communications (US) at Lumanity, leads the strategic development and execution of communication initiatives within the United States market. This role is crucial for translating complex scientific and commercial data into compelling product narratives that resonate with diverse stakeholders. Overseeing the communications practice, John Howley ensures Lumanity's deep experience in commercial affairs is applied to effectively position pharmaceutical and biotech products. The President, Communications (US) drives the creation of messaging that demonstrates product value and supports successful commercialization efforts. By crafting clear and impactful communications, John Howley empowers patients, providers, and payers to take timely and decisive action. This leadership function is essential for achieving sustainable market success and ensuring that the value of medical advances is effectively communicated across the US.